Joshua M. Mammen
Expertise in
23
conditions

Dr. Joshua M. Mammen

Surgical Oncology
505 S 45th St., 
Omaha, NE 
27 Years of Experience
Expertise in
23
conditions
505 S 45th St., 
Omaha, NE 

Overview

Joshua Mammen is a Surgical Oncologist practicing medicine in Omaha, Nebraska. He has been practicing medicine for over 27 years.

Dr. Mammen is highly rated in 23 conditions, according to our data. His clinical expertise encompasses Merkel Cell Carcinoma, Melanoma, Eccrine Porocarcinoma, Lymphadenectomy, and Ureteroscopy.

He is actively involved in clinical research, co-authoring 31 peer reviewed articles and participating in 7 clinical trials.

Graduate Institution

Boston University, 1999

Residency

University of Cincinnati College of Medicine, General Surgery

Specialties

Surgical Oncology

Licenses

Surgery in TX

Fellowships

University of Cincinnati College of Medicine, Research - 2004
University of Texas - MD Anderson Cancer Center, Complex General Surgical Oncology - 2009

Hospital Affiliations

Bellevue Medical Center
The Nebraska Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medica
  • EPO
  • HMO
  • PPO
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Wellmark
  • HMO
  • POS
View 5 Less Insurance Carriers -

Locations

Fred & Pamela Buffett Cancer Center - Nebraska Medical Center
505 S 45th St., Omaha, NE 68105

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma
A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 2
Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754)
Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754)
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Drug, Radiation, Procedure
Study Drugs: Doxorubicin, Ifosfamide, Pazopanib
Study Phase: Phase 2/Phase 3
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Randomized Phase II Study of Anti-PD1 Antibody [MK-3475 (Pembrolizumab)] Alone Versus Anti-PD1 Antibody Plus Stereotactic Body Radiation Therapy in Advanced Merkel Cell Carcinoma
A Randomized Phase II Study of Anti-PD1 Antibody [MK-3475 (Pembrolizumab)] Alone Versus Anti-PD1 Antibody Plus Stereotactic Body Radiation Therapy in Advanced Merkel Cell Carcinoma
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Biological, Radiation
Study Drug: Pembrolizumab
Study Phase: Phase 2
STAMP: Surgically Treated Adjuvant Merkel Cell Carcinoma With Pembrolizumab, a Phase III Trial
STAMP: Surgically Treated Adjuvant Merkel Cell Carcinoma With Pembrolizumab, a Phase III Trial
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Procedure, Other, Radiation, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation With Concomitant and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation With Concomitant and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
Enrollment Status: Active_not_recruiting
Publish Date: January 14, 2026
Intervention Type: Other, Radiation, Drug
Study Drug: Temozolomide
Study Phase: Phase 2
A Randomized Phase III Trial of Memantine and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Patients With Brain Metastases
A Randomized Phase III Trial of Memantine and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Patients With Brain Metastases
Enrollment Status: Completed
Publish Date: April 23, 2025
Intervention Type: Radiation, Drug
Study Phase: Phase 3
View 6 Less Clinical Trials

31 Total Publications

ASO Visual Abstract: Prospective Phase II Multicenter Trial of Ablation after Breast Lumpectomy Added To Extend (ABLATE) Intraoperative Margins for the Sole Local Treatment of Breast Cancer.
ASO Visual Abstract: Prospective Phase II Multicenter Trial of Ablation after Breast Lumpectomy Added To Extend (ABLATE) Intraoperative Margins for the Sole Local Treatment of Breast Cancer.
Journal: Annals of surgical oncology
Published: March 30, 2026
Similar Doctors
Expertise in
17
conditions
Dr. Quan P. Ly
Surgical Oncology
Expertise in
17
conditions
Dr. Quan P. Ly
Surgical Oncology

Fred & Pamela Buffett Cancer Center - Nebraska Medical Center

505 S 45th St., 
Omaha, NE 
 (0.3 miles away)
402-559-5600
Experience:
30+ years
Languages Spoken:
English
See accepted insurances

Quan Ly is a Surgical Oncologist practicing medicine in Omaha, Nebraska. She has been practicing medicine for over 30 years. Dr. Ly is highly rated in 17 conditions, according to our data. Her clinical expertise encompasses Pancreatic Cancer, Familial Pancreatic Cancer, Colorectal Cancer, Splenectomy, and Pancreatectomy.

Expertise in
15
conditions
Dr. James Reilly
Surgical Oncology
Expertise in
15
conditions
Dr. James Reilly
Surgical Oncology

Physicians Clinic Inc.

8111 Dodge St Ste 263, 
Omaha, NE 
 (4.0 miles away)
402-354-8163
Languages Spoken:
English
See accepted insurances

James Reilly is a Surgical Oncologist practicing medicine in Omaha, Nebraska. Dr. Reilly is highly rated in 15 conditions, according to our data. His clinical expertise encompasses Paget Disease of the Breast, Breast Cancer, Angiosarcoma, Intraductal Papilloma, and Lymphadenectomy.

Expertise in
11
conditions
Dr. Jason M. Foster
Surgical Oncology
Expertise in
11
conditions
Dr. Jason M. Foster
Surgical Oncology

Fred & Pamela Buffett Cancer Center - Nebraska Medical Center

505 S 45th St., 
Omaha, NE 
 (0.3 miles away)
402-559-5600
Experience:
32+ years
Languages Spoken:
English
See accepted insurances

Jason Foster is a Surgical Oncologist practicing medicine in Omaha, Nebraska. He has been practicing medicine for over 32 years. Dr. Foster is highly rated in 11 conditions, according to our data. His clinical expertise encompasses Pseudomyxoma Peritonei, Melanoma, Lump in the Abdomen, Splenectomy, and Bladder Reconstruction.

Frequently Asked Questions about Dr. Joshua M. Mammen

How do I make an appointment with Dr. Joshua M. Mammen?

You can book an appointment with Dr. Joshua M. Mammen by calling their office at 402-559-5600. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Joshua M. Mammen a top-rated expert for Merkel Cell Carcinoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Joshua M. Mammen is classified as an Distinguished expert for Merkel Cell Carcinoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Joshua M. Mammen specialize in?

While Dr. Joshua M. Mammen is a Surgical Oncology, they have specific expertise in Merkel Cell Carcinoma, Melanoma, and Eccrine Porocarcinoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Surgical Oncology.

Does Dr. Joshua M. Mammen participate in research or clinical trials?

Yes. Dr. Joshua M. Mammen has published 31 articles and abstracts on conditions like Merkel Cell Carcinoma. You can view a list of Dr. Joshua M. Mammen's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Joshua M. Mammen accept my insurance?

Dr. Joshua M. Mammen accepts most major insurance plans, including Aetna and Blue Cross Blue Shield. We recommend calling the office directly at 402-559-5600 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Mammen's expertise for a condition
ConditionClose
    View All 21 Advanced Conditions
    View All 14 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile